We recently published a list of 10 Value Stocks in Ken Fisher’s Portfolio. In this article, we are going to take a look at ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

It does not necessarily reflect the view of The Herald. An image of 11-year-old Kaliyah Coa has been released by police as they continue to search the River Thames for the missing schoolgirl. Kaliyah, ...

She is passionate about empowering others to protect life's most important assets. Wh... Michelle is a lead editor at Forbes Advisor. She has been a journalist for over 35 years, writing about ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. Researchers at Columbia University are in limbo ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

A fresh report on the U.S. life sciences sector is back from the lab with an inconclusive prognosis despite an improved investment environment in 2024. The niche industry struggled throughout 2024 in ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...